uniQure N.V. (NASDAQ:QURE – Get Free Report) Director Madhavan Balachandran sold 1,993 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $53,930.58. Following the transaction, the director directly owned 43,254 shares of the company’s stock, valued at $1,170,453.24. The trade was a 4.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
uniQure Price Performance
uniQure stock traded up $0.75 during mid-day trading on Friday, hitting $27.57. 835,627 shares of the company were exchanged, compared to its average volume of 2,601,234. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The business’s 50 day simple moving average is $22.31 and its two-hundred day simple moving average is $21.76. The company has a market capitalization of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50.
uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.
Hedge Funds Weigh In On uniQure
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on QURE shares. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Chardan Capital lifted their price objective on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Wolfe Research started coverage on uniQure in a research report on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, Royal Bank Of Canada raised uniQure from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $35.00 in a research report on Monday, March 9th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.83.
Check Out Our Latest Analysis on uniQure
uniQure Company Profile
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
Featured Articles
- Five stocks we like better than uniQure
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
